NCT05980065View on ClinicalTrials.gov

To Evaluate the Safety, Tolerability, and Pharmacokinetics After Subcutaneous Administration of C1K in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

December 20, 2022

Primary Completion Date

June 13, 2023

Study Completion Date

October 4, 2023

Conditions
Healthy Subjects
Interventions
DRUG

C1K

Subcutaneously administrate C1K 150mg at 0 Day 1, Day 8, Day 15

DRUG

C1K

Subcutaneously administrate C1K 300mg at 0 Day 1, Day 8, Day 15

DRUG

Placebo

Subcutaneously administrate placebo at 0 Day 1, Day 8, Day 15

DRUG

C1K

Subcutaneously administrate C1K 600mg at 0 Day 1, Day 8, Day 15

DRUG

C1K

Subcutaneously administrate C1K 900mg at 0 Day 1, Day 8, Day 15

DRUG

C1K

Subcutaneously administrate C1K 1200mg at 0 Day 1, Day 8, Day 15

Trial Locations (1)

03080

Seoul National University Clinical Trial Center, Seoul

Sponsors

Collaborators (1)

Ensol Biosciences, Inc.
All Listed Sponsors
collaborator

Ensol Biosciences, Inc.

UNKNOWN

lead

Seoul National University Hospital

OTHER

NCT05980065 - To Evaluate the Safety, Tolerability, and Pharmacokinetics After Subcutaneous Administration of C1K in Healthy Subjects | Biotech Hunter | Biotech Hunter